The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer

Margin-negative (R0) resection is the only potentially curative treatment for patients (pts) with pancreatic ductal adenocarcinoma (PDAC). Neoadjuvant multi-agent chemotherapy alone (MAC) vs MAC followed by neoadjuvant radiotherapy (MAC+RT) may be used to improve resectability and potentially survivorship. However, the optimal preoperative regimen is unknown.

Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Joseph Miccio, Wesley Talcott, Timil Patel, Henry Park, Michael Cecchini, Ronald Salem, Stacey Stein, Jeremy Kortmansky, Jill Lacy, Kimberly Johung, Krishan Jethwa Source Type: research